Tag Archives: evidence

What Trump’s budget proposal may mean for health research agency

Rebecca Vesely

About Rebecca Vesely

Rebecca Vesely is AHCJ's topic leader on health information technology and a freelance writer. She has written about health IT since the late 1990s for a variety of publications.

President Donald Trump’s budget proposal includes rolling a relatively obscure agency that conducts health care research into the National Institutes of Health, and cutting the NIH budget by $5.8 billion.

That small agency – the Agency for Healthcare Research and Quality, or AHRQ (pronounced “arc“)  – could be cut entirely or see its mission shrink drastically under the president’s plan. Reducing or eliminating AHRQ would have a significant effect on health system research and health IT adoption in communities across the country. Reporters have a number of ways to see how changes to AHRQ could affect health services in their region. Continue reading

While genetic tests proliferate, journalists cite the lack of scientific evidence

Joseph Burns

About Joseph Burns

Joseph Burns (@jburns18), a Massachusetts-based independent journalist, is AHCJ’s topic leader on health insurance. He welcomes questions and suggestions on insurance resources and tip sheets at joseph@healthjournalism.org.

Photo: Caroline Davis2010 via Flickr

Photo: Caroline Davis2010 via Flickr

The potential benefits of genetic testing are widely touted and drive greater interest in these tests – even though the validity of the science behind such testing remains unclear.

Charles Piller, the West Coast editor for Boston-based online news site Stat, recently reported on the lack of a firm scientific basis for a test that Proove Biosciences in Irvine, Calif., has been marketing as an “opioid risk” detector. Continue reading

Flaws, limits and conflicts: Tips to find study pitfalls #AHCJ16

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

At Health Journalism 2016 in Cleveland, Andrew M. Seaman and Hilda Bastian discussed shortcuts for weighing the likelihood a study’s answer is right, making sense of shifting bodies of evidence and cutting through researcher spin. Continue reading

Making the most of medical research sessions at #AHCJ16

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

road-to-cleveland-2Each year, the AHCJ conference includes a smorgasbord of opportunities to inform and enhance journalists’ knowledge and reporting. Topics include health care disparities, hospital performance reporting, age-specific conditions for youth and elderly alike – and, of course, what the medical research reveals about these and other subjects.

Even in sessions that focus on a specific population or a condition that doesn’t immediately seem relevant to medical research – such as how to cover the ongoing opioid epidemic – there likely are ways that the material intersects with research on that topic. If you’re looking for stories that might involve some digging in PubMed, here are some sessions to consider during Health Journalism 2016 in Cleveland, April 7-10. Continue reading

Time takes a critical look at breast cancer treatment

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Photo Annie Cavanagh, Wellcome Images

Photo: Annie Cavanagh, Wellcome Images

Siobhan O’Connor recently explored in a Time magazine piece an issue that has been gaining traction in both the medical world and the media reporting on it: the overtreatment of breast cancer.

Her story, “Why Doctors Are Rethinking Breast-Cancer Treatment,” opens with an anecdote from now-60-year-old Desiree Basila, who several years ago decided to do … nothing after receiving a diagnosis of ductal carcinoma in situ (DCIS), a stage 0 cancer in the breast ducts that was not invasive – and may never become so. What makes this opening anecdote striking was not simply Basila’s decision – one that has been discussed more often in recent years – but when it occurred: Continue reading